Press Release REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer Tokyo and Basking Ridge, NJ - (April 3, 2024) - Daiichi Sankyo (TSE: 4568) and Merck & Co., Inc, Rahway, NJ, USA announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd)in [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Daiichi Sankyo Co. Ltd. published this content on 03 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 April 2024 12:17:04 UTC.